Does the genotype of HHT patients with mutations of the ENG and ACVRL1 gene correlate to different expression levels of the angiogenic factor VEGF?

International Journal of Molecular Medicine

Volumn 22, Issue 5, 2008, Pages 575-580

  Sadick, Haneen ^a   Hage, Johanna ^a   Goessler, Ulrich ^a   Bran, Gregor ^a   Riedel, Frank ^a   Bugert, Peter ^a   Hoermann, Karl ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Activin receptor like kinase 1; Angiogenesis; Endoglin; Genotype; Hereditary hemorrhagic telangiectasia; Vascular endothelial growth factor

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; ENDOGLIN; VASCULOTROPIN; ACTIVIN RECEPTOR 2; ACVRL1 PROTEIN, HUMAN; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; UNCLASSIFIED DRUG; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FROZEN SECTION; GENE MUTATION; GENETIC SCREENING; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NOSE MUCOSA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RENDU OSLER WEBER DISEASE; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY;

ACTIVIN RECEPTORS, TYPE II; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; FEMALE; GENE EXPRESSION REGULATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NASAL MUCOSA; RECEPTORS, CELL SURFACE; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 59149089645     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000058     Document Type: Article

References (33)

1. Begbie ME, Wallace GM and Shovlin CL: Hereditary haemorrhagic telangiectasia (Osler Weber-Rendu syndrome): a view from the 21st century. J Postgrad Med 79: 18-24, 2003.
2. Guttmacher AE, Marchuk DA and White RI Jr: Hereditary hemorrhagic telangiectasia. N Engl J Med 333: 918-924, 1995.
3. Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, Kjeldsen AD and Plauchu H: Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 91: 66-67, 2000.
4. Bourdeau A, Faughnan ME, McDonald M-L, Paterson AD, Wanless IR and Letarte M: The potential role of modifier genes influencing transforming growth factor-β1 levels in the development of vascular defects in endoglin heterozygous mice with hereditary hemorrhagic telangiectasia. Am J Pathol 158: 2011-2020, 2001.
5. Sadick H, Sadick M, Gotte K, Naim R, Riedel F, Bran G and Hormann K: Hereditary hemorrhagic telangiectasia: an update on clinical manifestations and diagnostic measures. Wien Klin Wochenschr 118: 72-80, 2006.
6. McAllister KA, Grogg KM, Johnson DW, et al: Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 8: 345-351, 1994.
7. Johnson DW, Berg JN, Gallione CJ, et al: A second locus for hereditary hemorrhagic telangiectasia maps to chromosome 12. Genome Res 5: 21-28, 1995.
8. Johnson DW, Berg JN, Baldwin MA, et al: Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 13: 189-195, 1996.
9. Gougos A and Letarte M: Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J Biol Chem 265: 8361-8364, 1990.
10. Attisano L, Carcamo J, Ventura F, Weis FM, Massague J and Wrana JL: Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors. Cell 75: 671-680, 1993.
11. Oh SP, Seki T and Gross KA: Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci USA 97: 2626-2631, 2000.
12. Bourdeau A, Cymerman U, Paquet M, Meschino W, McKinnon WC and Guttmacher AE: Endoglin expression is reduced in normal vessels but still detectable in arteriovenous malformation of patients with hereditary hemorrhagic telangiectasia type 1. Am J Pathol 156: 911-923, 2000.
13. Jacobson BS: Hereditary hemorrhagic telangiectasia. A model for blood vessel growth and enlargement. Am J Pathol 156: 737-742, 2000.
14. Sabba C, Cirulli A, Rizzi R, et al: Angiogenesis and hereditary hemorrhagic telangiectasia. Acta Haematol 106: 214-219, 2001.
15. Dvorak HF, Brown LF, Detmar M and Dvorak AM: Vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146: 1029-1039, 1995.
16. Ferrara N: Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 56: 794-814, 1999.
17. Minagawa N, Nakayama Y and Hirata K: Correlation of plasma level and immunohistochemical expression of vascular endothelial growth factor in patients with advanced colorectal disease. Anticancer Res 22: 2957-2964, 2002.
18. Riedel F, Götte K, Schwalb J, Wirtz H, Bergler W and Hörmann K: Serum levels of vascular endothelial growth factor in patients with head and neck cancer. Eur Arch Otorhinolaryngol 257: 332-336, 2000.
19. Plate KH, Breier G, Weich HA and Risau W: Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature 359: 845-848, 1992.
20. Koch AE, Harlow LA and Haines GK: Vascular endothelial growth factor a cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 152: 4149-4156, 1994.
21. Makin AJ, Chung NAY, Silverman SH and Lip GYH: Vascular endothelial growth factor and tissue factor in patients with established peripheral artery disease: a link between angiogenesis and thrombogenesis? Clin Sci 104: 397-404, 2003.
22. Broll R, Erdmann H and Duchrow M: Vascular endothelial growth factor (VEGF) - a valuable serum tumour marker in patients with colorectal cancer? EJSO 27: 37-42, 2001.
23. Royen NV, Hoefer I and Buschmann I: Exogenous application of transforming growth factor beta 1 stimulates arteriogenesis in the peripheral circulation. FASEB J 16: 432-434, 2002.
24. Sadick H, Naim R, Sadick M, Hormann K and Riedel F: Plasma level and tissue expression of angiogenic factors in patients with hereditary hemorrhagic telangiectasia. Int J Mol Med 15: 591-596, 2005.
25. Sadick H, Naim R, Gossler U, Hormann K and Riedel F: Angiogenesis in hereditary hemorrhagic telangiectasia: VEGF165 plasma concentration in correlation to the VEGF expression and microvessel density. Int J Mol Med 15: 15-19, 2005.
26. Massod R, Ca J, Tulpule A, Zheng T, Hamilton A, Sharma S, Epina BM, et al: Interleukin 8 is an autocrine growth factor and a surrogate marker for kaposi's sarcoma: Clin Cancer Res 7: 2693-2702, 2001.
27. Folkman J and D'Amore PA: Blood vessel formation: what is its molecular basis? Cell 87: 1153-1155, 1998.
28. Tímár J, Döme B, Fazekas K, Janovics A and Paku S: Angiogenesis-dependent diseases and angiogenesis therapy. Pathol Oncol Res 7: 85-94, 2001.
29. Sadick H, Riedel F, Naim R, et al: Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica 90: 818-828, 2005.
30. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P and ten Dijke P: Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J 21: 1743-1753, 2002.
31. Cirulli A, Liso Areangelo, D'Ovidio Francesco, Mestice A, Pasculli G, Gallitelli M, et al: Vascular endothelial growth factor in patients with hereditary hemorrhagic teangiectasia. Acta Haematol 110: 29-32, 2003.
32. Hyodo I, Doi T, Endo H, Hosokawa Y, Nishikawa Y, Tanimizu M, Jinno K and Kotani Y: Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur J Cancer 34: 2041-2045, 1998.
33. Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Walters C and Selby PJ: Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 77: 956-964, 1998.